SAN DIEGO, Oct. 16 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.
(Nasdaq: ANDS) announced today that it will report third quarter 2008
financial results on Thursday, October 23, 2008, after the U.S. financial
markets close.
Anadys will hold a conference call and webcast to discuss its third
quarter 2008 financial results and highlights and to provide an update on its
development programs on Thursday, October 23, 2008 at 5:00 p.m. Eastern
Daylight Time. A live webcast of the call will be available online at
http://www.anadyspharma.com. A telephone replay will also be available
approximately one hour after completion of the call. To access the telephone
replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode
86226986. The webcast and telephone replay will be available through
November 6, 2008.
About Anadys
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
dedicated to improving patient care by developing novel medicines in the areas
of hepatitis C and oncology. For the treatment of chronic hepatitis C, the
Company is developing two potentially complementary agents, ANA598, a
non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug.
The Company is also developing ANA773 for the treatment of cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute 'forward-looking statements.' Such statements include, but
are not limited to, references to Anadys' strategy, development programs, and
ability to develop novel medicines in the areas of hepatitis C and oncology.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause Anadys' actual results to be materially
different from historical results or from any results expressed or implied by
such forward-looking statements. For example, the results of preclinical
studies may not be predictive of future results, and Anadys cannot provide any
assurances that ANA598 and ANA773 will not have unforeseen safety issues, will
have favorable results in future clinical trials or will receive regulatory
approval. Risk factors that may cause actual results to differ are discussed
in Anadys' SEC filings, including Anadys' Form 10-K for the year ended
December 31, 2007 and Anadys' Form 10-Q for the quarter ended June 30, 2008.
All forward-looking statements are qualified in their entirety by this
cautionary statement. Anadys is providing this information as of this date
and does not undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or
otherwise.
SOURCE Anadys Pharmaceuticals, Inc.
